☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4348039 (Sta ...

Exhibit 99.1 Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Norwood, MA, August 5, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended June 30, 2025. "The second half of 2025 is shaping up to be impactful, with scheduled data readouts anticipated for all three of our c ...

CRB-701 (Nectin-4 Targeting ADC) - Clinical data readouts are expected for CRB-701 in the second half of 2025, with complete dose optimization and RP2D determination expected in Q4 2025[5] - CRB-701 is designed to address unmet needs of PADCEV® by extending ADC half-life to reduce dosing frequency and enabling higher doses due to lower DAR and longer half-life[10] - Phase 1 dose escalation studies are ongoing, with continued expansion at 2 doses and dose optimization planned for HNSCC, cervical, and bladder tumors[17, 18] - In Phase 1 dose escalation studies, ocular toxicity was reduced from 66% in CSPC cohorts to 38% in Corbus cohorts through the use of prophylaxis and baseline selection[32] - Emerging combined safety profile of CRB-701 shows a Grade 3 or higher AE rate of 20% (n=15/75), compared to 58% for PADCEV® (n=179 of 310)[33] - Phase 1 data shows an ORR of 27% and DCR of 77% in Corbus patients (n=26), and an ORR of 28% and DCR of 68% in CSPC patients (n=25)[38] - In mUC patients, CRB-701 showed an ORR of 44% (4 out of 9) and a DCR of 78% (7 out of 9)[48] - In cervical cancer patients, CRB-701 showed an ORR of 43% (3 out of 7) and a DCR of 86% (6 out of 7)[52] - In HNSCC patients, CRB-701 showed an ORR of 4 out of 7 patients and a DCR of 6 out of 7 patients[57] Financials - As of March 31, 2025, the company had $133 million in cash, cash equivalents, and investments, with approximately 122 million common shares outstanding (~140 million fully-diluted shares)[5]

Core Insights - Corbus Pharmaceuticals has initiated the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a peripherally restricted CB1 inverse agonist aimed at treating obesity, following the single ascending dose (SAD) study [2][4] - The MAD study is designed to assess the safety, tolerability, and pharmacokinetics of CRB-913 with a once-daily dosing regimen over 7 days in healthy volunteers [3][4] - Preliminary data from the SAD study indicates no treatment-related neuropsychiatric events, even at higher doses than expected for efficacy [4][5] Company Overview - Corbus Pharmaceuticals is a clinical-stage company focused on oncology and obesity, with a pipeline that includes CRB-701, CRB-601, and CRB-913 [6] - CRB-913 is characterized as an oral small molecule inverse agonist of the CB1 receptor, designed to minimize brain penetration and reduce the risk of neuropsychiatric side effects compared to previous drugs in this class [5][6] - The company is headquartered in Norwood, Massachusetts, and aims to leverage innovative scientific approaches to address serious illnesses [6]

Core Insights - Corbus Pharmaceuticals has initiated the dosing of the first participant in the PD-1 combination arm of its Phase 1 study for CRB-701, targeting solid tumors [1] - The company is experiencing a strong enrollment rate in the CRB-701 program, with a focus on advanced solid tumors associated with high Nectin-4 expression [2] Company Overview - Corbus Pharmaceuticals is a clinical-stage company focused on oncology and obesity, aiming to develop innovative treatments targeting well-understood biological pathways [4] - The company's pipeline includes CRB-701, an antibody-drug conjugate targeting Nectin-4, CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor inverse agonist for obesity [4] Study Details - The Phase 1 study (NCT06265727) consists of three parts: Part A (dose escalation), Part B (dose optimization), and Part C (dose expansion), with the company expecting to provide a data update and establish the recommended Phase 2 dose in Q4 2025 [2] - The initial dose escalation evaluated four doses: 1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg, and 4.5 mg/kg [2] Product Information - CRB-701 (SYS6002) is a next-generation antibody-drug conjugate that utilizes a cleavable linker and a homogeneous drug-antibody ratio of 2, with MMAE as the payload [3] - Nectin-4 is recognized as a clinically validated tumor-associated antigen in urothelial cancer [3] Enrollment and Data Update - Over 100 participants have been dosed in the monotherapy cohort, with a priority focus on Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancer [7] - A data update is scheduled for later this year [7]

NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fire side chat at the Piper Sandler 3rd Annual Virtual Obesity Symposium, to be held on June 26, 2025. The event will include presentations by key opinion leaders and fireside chats with companies developing obesity therapeutics. Piper Sandler clients can register for the event thr ...

Core Insights - Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) experienced a significant increase in stock value, more than doubling over the course of 2024 before facing a sharp decline [1] Group 1: Company Overview - The stock value of Corbus Pharmaceuticals surged significantly, indicating potential investor interest and market volatility [1] - The analysis emphasizes the importance of understanding the science behind biotech investments, highlighting the complexities involved in clinical trials and the biotech sector [1] Group 2: Analyst Perspective - The analyst has a PhD in biochemistry and extensive experience in analyzing clinical trials and biotech companies, which adds credibility to the insights provided [1] - There is a potential for the analyst to initiate a long position in CRBP within the next 72 hours, suggesting a possible shift in investment strategy [2]

Summary of Corbus Pharmaceuticals Holdings (CRBP) 2025 Conference Call Company Overview - Corbus Pharmaceuticals is a drug discovery and development company based in Norwood, Massachusetts, with a team of approximately 33 employees [4][5] - The company has a pipeline consisting of three clinical assets: two in oncology and one in obesity, all of which are expected to have clinical readouts in the second half of 2025 [4][5] Key Points on Oncology Programs - The company is currently optimizing doses for its oncology program, specifically for MUC, cervical, and head and neck cancers, with results anticipated in Q4 2025 [6][7] - The focus is on three tumor types, with a significant number of patients expected to be presented at an upcoming oncology conference [8][12] - The company does not prioritize bladder cancer due to competition from established therapies like PADCEV plus Keytruda [9][10] - Benchmarks for head and neck and cervical cancers are established, with expected overall response rates (ORR) of 36% and 24%, respectively [10][11] Collaboration with CSPC - Corbus has a positive and constructive relationship with its partner CSPC, which is expected to present dose optimization data in the second half of the year [14][15] - The company has observed significant differences in patient management and trial design between the U.S. and China, particularly regarding patient adherence and quality of life considerations [17][18][19] Insights on Clinical Practices - The cultural differences in clinical practices between the West and China have led to lower discontinuation rates in Chinese trials compared to U.S. trials [17][19][20] - The company is focused on ensuring patient comfort while maintaining adherence to the study protocols [20][21] Obesity Program (CB1 Inverse Agonist) - The obesity program is entering a phase where data from a SAD/MAD study in healthy volunteers is expected, which will inform the next steps in the development plan [27][29] - The company anticipates that the obesity drug will lead to weight loss, supported by a clinically validated mechanism of action [30][31] - The focus is on ensuring a clean safety profile, particularly concerning neuropsychiatric adverse events [31][34] Competitive Landscape in Obesity - The obesity market is competitive, dominated by incretin-based therapies, but Corbus aims to position its CB1 inverse agonist as a complementary option for patients who are intolerant to existing therapies [50][54] - The potential for the drug to serve as a maintenance therapy after initial weight loss with injectable therapies is highlighted as a significant market opportunity [55][56] Financial Position - Corbus ended the quarter with $133 million in cash, providing a runway until mid-2027 [57] Future Outlook - The company is preparing for a monotherapy dose escalation study for its highest-risk program targeting TGF beta, with data expected by the end of the year [58][59]

Industry Overview - The obesity market is rapidly expanding, driven by the success of GLP-1 therapies Wegovy and Zepbound, and is projected to reach $100 billion by 2030 [1] - There is a growing interest in cannabinoid (CBD)-based therapies as companies seek to innovate beyond GLP-1s for weight management [2] - The cannabis industry is also experiencing significant growth, expected to surpass $200 billion by 2032, although direct investments in cannabis companies have been challenging due to regulatory issues [3] Company Analysis Novo Nordisk - Novo Nordisk is a leader in obesity treatments with its semaglutide products, Wegovy and Ozempic, but faces increasing competition from Eli Lilly [5] - The company entered the CBD space by acquiring Inversago Pharmaceuticals in 2023, adding monlunabant, an investigational oral cannabinoid drug for metabolic diseases [6] - A phase IIa study on monlunabant showed statistically significant weight loss compared to placebo, but higher doses had diminishing returns; a phase IIb study is planned to find an optimal dose [7] - EPS estimates for 2025 have increased from $3.81 to $3.84, while 2026 estimates have slightly decreased from $4.66 to $4.64; the stock has declined about 21% year to date due to competition and regulatory challenges [8] Corbus Pharmaceuticals - Corbus' lead CBD candidate, CRB-913, targets the same CB1 receptor as monlunabant and is currently in phase I studies, with results expected in Q3 2025 [9] - Preclinical data suggest CRB-913 may have advantages over previous therapies, with a significantly lower brain-to-plasma ratio, indicating reduced neuropsychiatric side effects [10] - Corbus is also developing two oncology drugs, CRB-701 and CRB-601, with CRB-701 in phase I/II studies [11] - Loss per share estimates for 2025 have increased from $5.47 to $6.34, and for 2026 from $5.30 to $5.39; the stock has declined 36% year to date, reflecting regulatory volatility [12][13] Skye Bioscience - Skye Bioscience is developing nimacimab, a monoclonal antibody targeting the CB1 pathway, currently in a phase II study evaluating its efficacy as a monotherapy and in combination with Wegovy [14] - Nimacimab is designed to minimize brain penetration while maintaining metabolic effects, with early studies showing no adverse psychiatric events [15] - Loss per share estimates for 2025 have widened from $1.27 to $1.31, and for 2026 from $1.48 to $1.52; the stock has lost 27% year to date due to financial concerns and lack of commercial revenues [16]

Company Overview - Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity, aiming to help patients overcome serious illnesses through innovative scientific approaches targeting well-understood biological pathways [2] - The company's pipeline includes three key products: CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells; and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for obesity treatment [2] Upcoming Events - Yuval Cohen, Ph.D., CEO of Corbus, will provide a corporate update and engage in one-on-one investor meetings at the Jefferies Global Healthcare Conference scheduled for June 3-5, 2025, in New York [1] - The presentation by Corbus is set for June 4, 2025, at 4:55 p.m. ET [2]